My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACELYRIN, INC. - Common Stock
(NQ:
SLRN
)
2.270
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
2.270
Bid (Size)
2.250 (3)
Ask (Size)
2.320 (4)
Prev. Close
2.270
Today's Range
2.270 - 2.270
52wk Range
1.845 - 6.520
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades
September 29, 2025
Via
Stocktwits
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
May 13, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Performance
YTD
-31.2%
-31.2%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+3.2%
+3.2%
1 Year
-62.7%
-62.7%
More News
Read More
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
May 06, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 01, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
April 16, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
3 Biopharmaceutical Stocks Bucking the Sell-Off
April 10, 2025
Via
MarketBeat
Topics
World Trade
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
April 07, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
March 13, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
March 04, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
March 04, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
February 23, 2025
Via
Stocktwits
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders
February 21, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
These stocks are moving in today's pre-market session
February 21, 2025
Via
Chartmill
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
February 20, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
February 20, 2025
Via
Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, SLRN, PTMN, HEES on Behalf of Shareholders
February 18, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PLYA, SLRN, NVRO, AMPS on Behalf of Shareholders
February 10, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
February 10, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, TGI, PTMN on Behalf of Shareholders
February 10, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
February 06, 2025
From
Halper Sadeh LLC
Via
Business Wire
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
February 06, 2025
From
Ademi & Fruchter LLP
Via
Business Wire
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Nasdaq Down 1.5%; RPM Posts Upbeat Results
January 07, 2025
Via
Benzinga
Dow Surges Over 100 Points; US Trade Deficit Widens In November
January 07, 2025
Via
Benzinga
Topics
Stocks
Frequently Asked Questions
Is ACELYRIN, INC. - Common Stock publicly traded?
Yes, ACELYRIN, INC. - Common Stock is publicly traded.
What exchange does ACELYRIN, INC. - Common Stock trade on?
ACELYRIN, INC. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACELYRIN, INC. - Common Stock?
The ticker symbol for ACELYRIN, INC. - Common Stock is SLRN on the Nasdaq Stock Market
What is the current price of ACELYRIN, INC. - Common Stock?
The current price of ACELYRIN, INC. - Common Stock is 2.270
When was ACELYRIN, INC. - Common Stock last traded?
The last trade of ACELYRIN, INC. - Common Stock was at 05/20/25 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.